Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H12N4O4S |
| Molecular Weight | 284.292 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=NC3=C2N=CNC3=S
InChI
InChIKey=NKGPJODWTZCHGF-KQYNXXCUSA-N
InChI=1S/C10H12N4O4S/c15-1-4-6(16)7(17)10(18-4)14-3-13-5-8(14)11-2-12-9(5)19/h2-4,6-7,10,15-17H,1H2,(H,11,12,19)/t4-,6-,7-,10-/m1/s1
| Molecular Formula | C10H12N4O4S |
| Molecular Weight | 284.292 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/3412035Curator's Comment: Description was created based on several sources, including
https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=39497
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3412035
Curator's Comment: Description was created based on several sources, including
https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=39497
THIOINOSINE (Methylmercaptopurine riboside, NSC- 40774) is a purine derivative with antineoplastic and anti-angiogenic properties. THIOINOSINE is readily converted in cells to its active form, 6-methylmercaptopurine ribonucleoside 5'- monophosphate (MMPR-P), by the enzyme adenosine kinase. THIOINOSINE inhibits amidophosphoribosyltransferase, the first committed step in de novo purine synthesis, and inhibits fibroblast growth factor-2 (FGF2)-induced cell proliferation. It has been used similarly to Mercaptopurine in the treatment of Leukemia. It has being tested in clinical trials for advanced pancreatic cancer.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Bacillus anthracis spore germination Sources: https://www.ncbi.nlm.nih.gov/pubmed/20921305 |
40.0 µM [IC50] | ||
Target ID: Murine leukemia cells growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/1906107 |
68.0 nM [IC50] | ||
Target ID: Free radical scavenging Sources: https://www.ncbi.nlm.nih.gov/pubmed/19692149 |
3.9 µM [IC50] | ||
Target ID: Murine lymphoma cells growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/221658 |
250.0 nM [EC50] | ||
Target ID: Q63433 Gene ID: 29355.0 Gene Symbol: Pkn1 Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1309569 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Captopril and 6-mercaptopurine: whose SH possesses higher antioxidant ability? | 2009-12 |
|
| Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides. | 1982-11 |
|
| Purine analogs as potential anticytomegalovirus agents. | 1969-09 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1060503
300 mg/m2/day by rapid i.v. injection
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1309569
THIOINOSINE blocked PKN with apparent Ki values between 100 and 500uM in PC12 pheochromocytoma cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:23:43 GMT 2025
by
admin
on
Mon Mar 31 18:23:43 GMT 2025
|
| Record UNII |
46S541971T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C574
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
||
|
NCI_THESAURUS |
C1556
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
D013868
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
PRIMARY | |||
|
DTXSID5046019
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
PRIMARY | |||
|
209-371-5
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
PRIMARY | |||
|
46S541971T
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
PRIMARY | |||
|
4988-64-1
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
100000127651
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
PRIMARY | |||
|
676166
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
PRIMARY | |||
|
C877
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
PRIMARY | |||
|
574-25-4
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
PRIMARY | |||
|
4911
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
PRIMARY | |||
|
CHEMBL448290
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
PRIMARY | |||
|
SUB33710
Created by
admin on Mon Mar 31 18:23:43 GMT 2025 , Edited by admin on Mon Mar 31 18:23:43 GMT 2025
|
PRIMARY |